Please note that following on from information provided to NICE by the company in February 2011, the appraisal of Quetiapine for the treatment of generalised anxiety disorder [ID347] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
|
Status
|
Discontinued
|
|
Technology type
|
Medicine
|
|
Decision
|
Selected
|
| Process |
TA
|
| ID number |
347
|
| Referral date |
01 June 2010 |
|
Topic area
|
- Mental health and behavioural conditions
- Public health
|
Provisional Schedule
| Closing date for invited submissions / evidence submission: |
9 December 2010 |
| 1st appraisal committee meeting: |
TBC |
Project Team
| Communications manager: |
Alice Law
|
| Executive Lead: |
Andrew Dillon |
| Project manager: |
Liz Walker
|
| Technical Lead: |
Raisa Sidhu |
Email enquiries